C(-260)T polymorphism in the promoter of CD14 gene is not associated with myocardial infarction in the Tunisian population

Riad Jemaa (1), Yousra Sediri (1), Amani Kallel (1), Mhammed Sami Mourali (2), Moncef Fekk (1), Monia Elasmi (1),Sameh Haj-Taïeb (1), Haïfa Sanhaji (1), Rachid Mechmeche (2), Nazih Kaabachi (1)

(1) Hôpital La Rabta, Biochimie, Tunis, Tunisie - (2) Hôpital La Rabta, Cardiologie, Tunis, Tunisie

Introduction: Recent finding suggest that inflammation plays a role in atherosclerosis and its acute complications. Several known mechanisms may play at least a partial role in this process. One of the most likely mechanisms involves lipopolysaccharide (LPS) and its receptor, CD14. The C(-260)T single nucleotide polymorphism in the promoter region of the CD14 receptor gene has been reported to be associated with a higher risk of MI. Others studies, however, have not corroborated these findings. Considering the contradictory results, the aim of the present study was to investigate the possible association between the CD14 C(-260)T polymorphism and the risk of MI in the Tunisian population.

Material and Methods: A total of 333 Tunisian patients with MI and 345 healthy controls were included in the study. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.

Results: The frequency of TT homozygous genotype for the CD14 C(-260)T polymorphism was 24.9% in MI patients and 24.0% in the control group. However, the genotype distribution and allele frequencies were not significantly different between MI and controls subjects. Moreover, the odds ratio for MI associated with the T allele failed to reach statistical significance (OR=1.08; 95% CI: 0.86 - 1.34; P=NS).

Conclusion: These results do not support the hypothesis that the C(-260)T polymorphism of CD14 gene contributes to the genetic susceptibility to MI in the Tunisian population studied.

Association of rs 2781666 G/T polymorphism of arginase 1 gene with myocardial infarction in the Tunisian population

Yousra Sediri (1), Amani Kallel (1), Mhammed Sami Mourali (2), Monia Elasmi (1), Amani Kallel (1), Sameh Haj-Taïeb (1), Haïfa Sanhaji (1), Rachid Mechmeche (2), Riadh Jemaa (1), Nazih Kaabachi (1)

(1) Hôpital la Rabta, Biochimie, Tunis, Tunisie - (2) Hôpital la Rabta, Cardiologie, Tunis, Tunisie

Introduction: Arginase I (ARG I) is the final enzyme of the urea cycle that converts L-arginine to urea and ornithine. Emerging evidence have identified ARG I as a critical regulator for nitric oxide (NOS) production via nitric oxide synthase (NOS). Therefore upregulation of ARG I inhibit NOS-mediated NO and may contribute to endothelial dysfunction. In addition, pathophysiological role of ARG I on vascular disease have been extensively documented, and some recent studies support a role for ARG I in the development and complications of coronary artery disease (CAD). The aim of the present study is to investigate the possible association between rs 2781666 G/T polymorphism of ARG I gene and myocardial infarction (MI) in the Tunisian population.

Methods: In a case-control study, a total of 321 patients with MI and 436 controls were included. The rs 2781666 G/T polymorphism of ARG I was determined by PCR-RFLP analysis.

Results: Patients with MI had significantly higher frequency of TT genotype compared to controls (10.3% vs 6.7%; OR (95% CI), 2.05 (1.09 - 3.52), P=0.009). The MI patients showed higher frequency of T allele compared to the controls (0.32 vs 0.23, OR (95% CI), 1.58 (1.25 - 2.00), P=0.001). The association between rs 2781666 G/T polymorphism of ARG I gene and MI was no longer significant after adjustment for other well established risk factors.

Conclusion: Our results revealed a significant but not independent association between rs2781666 G/T polymorphism of ARG I gene and (MI) in the Tunisian population.
Objective: Evaluation by radio frequency in real-time, the quality of arterial rigidity in patients with cardiovascular risk factors.

Method: 3 measurements each carotid artery to determine coefficients, parameters rigidity, velocity of wave of pulse according by age. Quality of the rigidity of the arterial wall is measured from the velocity of the wave of pulse (PWV), variation of arterial diameter blood pressure on level of humeral artery, with measures of rigidity parameters.

Results: 2 carotid axes: 200 patients, 3 groups (age 30-69) according by age, sex, race 2 groups: white race, dyslipidemia, type II diabetes, smoking: according by sex, 1 group: 60 M, white race, the 2 group: 40 F (white race), 3 group 50 patients (hypertension, overweight) according to the sex and race; in 2 sub-groups: group A 25 M (20 white race, 5 black) group B 25 F white race. Brachial blood pressure calculated to obtain the velocity of the wave of pulse, coefficients of arterial rigidity, local pressure. The pathological wave of pulse >13m/s, coefficients of rigidity: >11, β > 20. In the 2 groups (10% men, 8% women) had pathological >11, β>20 and velocity propagation of PWV >13 m/s. In 3 group 20% M, 12% F with hypertension, pathological rigidity, local pressure systolic increased despite the treatment.

Conclusion: QAS non invasive measure of arterial rigidity on carotid, independent marker, in patients with cardiovascular risk factors, study the local and central blood pressure hypertensive patients to better control a pharmacological therapy. QAS by radiofrequency calculation of arterial rigidity on carotid level, parameters of rigidity, , and velocity of propagation of wave of pulse, the local and central pressure of the studied artery. In 1 and 2 group, patients with nicotinic intoxication and risk factors, in 3 group (hypertension, overweight) not find pathological data neither differences according to the sex and the race among all hypertensive patients. 2 patients of race black, 5 of the sub-group (hypertension) with pathological coefficient > 11.

QAS: calculation of arterial rigidity, RF: radio frequency, PWV (wave velocity pulse), β: stiffness parameters.

262

High density lipoprotein-anionic peptide factor effect on reverse cholesterol transport in type 2 diabetic patients with and without coronary artery disease

Nebil Attia (1), Amel Nakbi (2), Khaldoun Ben Hamda (3), Sonia Hammami (4), Raaji Chilaba (2), Anne-Marie Lorec (5), Nicolle Donungo (6), Henri Portugal (5), Françoise Chanussot (6), Denis Lainor (6), Mohamed Hammami (2)

(1) Faculté des Sciences de Bizerte, Laboratoire de Biochimie, Bizerte, Tunisie - (2) UR Nutrition et Déforders Métaboliques, Faculté de Médecine de Monastir, Monastir, Tunisie - (3) Service de Cardiologie, CHU de Monastir, Monastir, Tunisie - (4) Médecine Interne, CHU de Monastir, Monastir, Tunisie - (5) Laboratoire de Biochimie et Centre ARCOL, Hôpital Sainte Marguerite, Marseille, France - (6) UMR 476 INSERM/1260 INRA, Marseille, France

Objectives: To verify if HDL3 Anionic Peptide Factor (HDL3-APF) is as an apolipoprotein that promotes the reverse cholesterol transport.

Design and Methods: We investigated a possible association between plasma HDL3-APF concentration, cholesterol efflux from Fu5AH cells and cholesteryl ester transfer protein (CETP) activity in type 2 diabetic patients with coronary artery disease (CAD) (n=36), those without CAD (n=20), and 37 healthy subjects.

Results: Plasma APF concentrations were decreased in diabetics with CAD compared to controls (p<0.01). Cellular cholesterol efflux was decreased in diabetics without and with CAD, (p<0.01 and p<0.001 respectively). CETP activity was significantly elevated in all patient groups. Multiple linear regression analysis shows that cholesterol efflux was independently and positively related only to APF concentrations in whole population and controls.

Conclusions: APF is likely to be a key independent factor for promoting cellular cholesterol efflux in healthy subjects. However this association is altered in type 2 diabetes.